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C A N C E R
A biomimetic pancreatic cancer on-chip reveals 
endothelial ablation via ALK7 signaling
Duc-Huy T. Nguyen1*, Esak Lee2,3*†, Styliani Alimperti2,3, Robert J. Norgard4, Alec Wong2,  
Jake June-Koo Lee5, Jeroen Eyckmans2,3, Ben Z. Stanger4, Christopher S. Chen1,2,3‡
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, lethal malignancy that invades adjacent vasculatures and 
spreads to distant sites before clinical detection. Although invasion into the peripancreatic vasculature is one of the 
hallmarks of PDAC, paradoxically, PDAC tumors also exhibit hypovascularity. How PDAC tumors become hypo-
vascular is poorly understood. We describe an organotypic PDAC-on-a-chip culture model that emulates vascular 
invasion and tumor–blood vessel interactions to better understand PDAC-vascular interactions. The model features 
a 3D matrix containing juxtaposed PDAC and perfusable endothelial lumens. PDAC cells invaded through intervening 
matrix, into vessel lumen, and ablated the endothelial cells, leaving behind tumor-filled luminal structures. Endo-
thelial ablation was also observed in in vivo PDAC models. We also identified the activin-ALK7 pathway as a mediator 
of endothelial ablation by PDAC. This tumor-on-a-chip model provides an important in vitro platform for investi-
gating the process of PDAC-driven endothelial ablation and may provide a mechanism for tumor hypovascularity.
INTRODUCTION
Although the diagnosis and treatment of cancer in its earliest stages 
has substantially improved outcomes in many tumors, survival rates 
in patients with tumors that have spread to distant sites remain dismal 
(1). Hence, the vast majority of cancer mortalities stem from metastasis 
and its complications (2). Metastasis is a final product of a chain of 
multiple complex steps, including local spread of cancer cells at primary 
sites of origin, invasive entry into nearby vasculature (intravasation), 
exit from vasculature (extravasation), and growth at distant organ sites 
(3). To complete the metastasis cascade, tumor cells need to extensively 
interact with the vasculature. However, the interactions between 
cancer cells and blood vessels in particular are poorly understood.
One of the many examples of poorly understood tumorendo­
thelium interactions is in pancreatic ductal adenocarcinoma (PDAC). 
PDAC is a highly metastatic cancer whose cancer cells have been 
shown to escape the tumor and enter the circulation at the very earliest 
stages of tumor progression (4, 5). The vast majority of patients once 
diagnosed with PDAC are already at the later stages of the disease (6). 
At the same time, tumor masses from these patients generally exhibit 
hypovascularity or a paucity of capillary vessels within these tumors 
(7). Hence, there is an unusual yet poorly understood transition in inter­
actions between tumor and the blood vessels in PDAC: At early stages, 
nearby blood vessels are essential in providing a means for tumor cells 
to gain access to the circulation, but at later stages, they are absent 
and can limit chemotherapeutic drug delivery to the tumors. Thus, 
understanding these tumor­ endothelium interactions within PDAC 
will provide important insights into PDAC tumor biology.
In part, a lack of detailed understanding of tumor­vessel inter­
actions in PDAC is due to difficulties in observing and studying 
these interactions in traditional models of tumor invasion. Al­
though a few histologic studies of patient samples have observed the 
extensive invasion of tumor cells into the vasculature (8–10), follow­up 
in vivo studies in mice have not advanced our understanding of this 
phenomenon owing to the complexity of animal models (11) and 
challenges in spatiotemporal imaging of tumor­vessel interactions 
in internal organs, such as pancreas (12). Alternative to in vivo 
approaches, recent advances in microfluidic microphysiological 
systems have allowed the generation of blood vessel–tumor inter­
faces in vitro (13–18). Early studies using these in vitro cultures 
to model the interactions between tumor cells with two­dimensional 
(2D) planar or 3D vessel­ like structures have demonstrated the 
value of juxtaposing tumor cells with the vascular compartment, 
especially in the context of investigating extravasation and intrava­
sation properties (14, 15, 19–21). However, so far, these models 
have not been used to study interactions between malignant PDAC 
and blood vessels.
To achieve a deeper understanding of tumor­endothelium inter­
actions in PDAC, we describe here a model system in which a bio­
mimetic ductal channel containing PDAC cells is juxtaposed to a 
rudimentary blood vessel consisting of an endothelialized, perfused 
lumen. Using this model, we observed that PDAC tumor cells can 
invade and remove the vascular endothelium to leave behind tumor­ 
lined and tumor­filled luminal structures, a process we refer to as 
endothelial ablation. We further validated our findings in in vivo 
PDAC models and identified a crucial role for activin­ALK7 signaling 
in mediating endothelial ablation in PDAC. On the basis of our 
studies, we propose that endothelial cell ablation by tumor cells via 
the activin­ALK7 signaling pathway may be a potential mechanism 
to explain hypovascularity in PDAC.
RESULTS
An organotypic model of PDAC exhibits 3D invasion 
and ablation of endothelial cells
To examine the process of PDAC invasion, we engineered an 
organotypic model of PDAC building on a previously developed 
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vessel­on­a­chip (18). Briefly, our PDAC organotypic model is 
composed of two hollow cylindrical channels, which are completely 
embedded into 3D collagen matrix (Fig. 1A). In one of the channels, 
we seeded endothelial cells to form a biomimetic blood vessel, as 
previously described (18). In a parallel channel, we seeded primary 
mouse pancreatic cancer cells PD7591 and allowed them to adhere 
to form a monolayer of epithelial cells to mimic a ductal compart­
ment of a pancreatic duct. To study the interactions of PDAC cells 
with the blood vessels, we performed a screening experiment 
wherein different chemotactic agents were introduced into the bio­
mimetic blood vessel and found that a gradient of fetal bovine 
serum (FBS) most efficiently stimulated invasion of pancreatic 
cancer cells into the collagen matrix (fig. S1, A to D). Character­
ization of the gradient using 21­kDa fluorescein isothiocyanate 
dextran (FITC­dextran) showed a gradual loss in the steepness of 
the gradient (fig. S1E), prompting us to administer FBS daily in 
the endothelial channel to maintain the FBS gradient during the 
course of the experiments.
Upon stimulation with FBS, the PDAC cells in the biomimetic 
ductal channel began to proliferate to form a multilayer of cells (fig. S2). 
By day 4, PD7591 cells began to invade into the matrix toward the 
endothelial lumen. The invasion was collective, with epithelial cells 
remaining in contact with each other, to form branched structures 
reminiscent of epithelial morphogenesis (Fig. 1B). The presence of 
the endothelium increased the migration speed of PD7591 in 
response to the FBS gradient (Fig. 1B), until reaching the engineered 
blood vessel. Upon contact with the biomimetic blood vessel, the 
PDAC cells wrapped around the blood vessel and spread along the 
Fig. 1. Organotypic model for PDAC-on-a-chip to capture pancreatic tumor vascular invasion. (A) Schematic of PDAC-on-a-chip with a biomimetic blood vessel and 
a pancreatic cancer duct. The microfluidic device is composed of two hollow cylindrical channels embedded within 3D collagen matrix. One channel was seeded with 
endothelial cells to form a perfusable biomimetic blood vessel, while the other channel was seeded with pancreatic cancer cells to form a pancreatic cancer duct. 
Phase-contrast image shows seeded cells in the device before PDAC migration. (B) Average invasion distance of a PDAC cell line, YFP PD7591, toward a gradient of FBS 
with and without human umbilical vein endothelial cells (HUVECs). The presence of HUVECs increased the migration speed of PD7591 (n = 3 individual experiments). 
Representative phase-contrast images of PD7591 migration at days 0 and 8 demonstrated the collective migration of PDAC invasion. (C) YFP PD7591 (in green) invaded 
toward the biomimetic blood vessel (in red), migrated along the vessel (i), and wrapped around the blood vessel, as shown in the cross-sectional image of the biomimetic 
blood vessel (ii). (D) A confocal image of a section of the blood vessel (in red) invaded by YFP PD7591 (in green) showed that part of the blood vessel was ablated by 
cancer cells in our organotypic model (i and ii). (E) Apoptosis, marked by cleaved caspase-3 staining (in white), was observed in endothelial cells (in red) during invasion of 
YFP PD7591 (in green) in the blood vessels in our 3D PDAC organotypic model. Endothelial cells in all images were stained with anti-CD31 antibody. YFP PD7591 was 
restained with FITC-conjugated anti-GFP (green fluorescent protein) antibody. Cell nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (in blue). Error bars are SEM.
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length of the blood vessel before invading into the vessel itself 
(Fig. 1C, i and ii, and movie S1).
During PD7591 invasion into the blood vessel, we observed that 
part of the blood vessel was occupied by the tumor PD7591 cells 
(Fig. 1D, i and ii, and movie S2), a finding that was replicated with 
three additional primary mouse PDAC cell lines and a human pan­
creatic cancer cell line (fig. S3). As the PDAC cells invaded and 
occupied the lumen of the biomimetic blood vessels, we also 
observed apoptotic endothelial cells in proximity to the PDAC 
cells (Fig. 1E), whereas endothelial cells in the biomimetic blood 
vessels without tumor invasion exhibited no apoptotic activity 
(fig. S4A). In our 3D organotypic model, our endothelium deposited 
a collagen IV layer, while the PDAC cells in the biomimetic pancreatic 
cancer duct did not deposit collagen IV (fig. S4B). We also observed 
that, as the tumor cells ablated the endothelial cells in the 3D bio­
mimetic blood vessel, the collagen IV layer deposited by the endo­
thelium gradually disappeared (fig. S4C). We collectively refer to 
this process as endothelial ablation, where the PDAC tumor cells 
invade the blood vessels and ablate the endothelial cells, leaving 
behind tumor­lined and tumor­filled luminal structures.
Endothelial ablation is observed in in vivo  
tumor models of PDAC
To verify that the used tumor cells PD7591 also ablated endothelial 
cells in vivo and further confirm that the biomimetic model repro­
duces an in vivo process that occurs in pancreatic cancers, we 
subcutaneously inoculated the same tumor cells into mice. After the 
tumor volume reached approximately 400 mm3, we resected the 
tumor, including the adjacent area around the tumor, for analysis. 
Immunohistochemical staining for cleaved caspase­3 and CD31 
showed that endothelial cells were apoptotic in the PDAC tumor 
in vivo (Fig. 2A). In contrast, control mice injected with Matrigel 
alone had a minimal amount of apoptotic endothelial cells (fig. S5A). 
Because tumor cells PD7591 did not deposit collagen IV in our 
in vitro and in vivo experiments (fig. S4, B and D), while blood 
vessels in vivo were surrounded by collagen IV (fig. S4, E and F), we 
stained for endomucin or CD31 as endothelial cell markers and 
collagen IV (a basement membrane protein in vessels) to identify 
blood vessels in PDAC tumors. A subset of vessel lumens in the 
tumor­containing regions was mosaically lined by both endothelial 
and PDAC cells (Fig. 2B, red arrows), and several collagen IV–lined 
lumens, reminiscent of blood vessels, were lined luminally with 
only PDAC cells (Fig. 2B, yellow arrows). These data are aligned 
with our in vitro findings (Fig. 1, D and E), therefore suggesting that 
our biomimetic model of PDAC captures a relevant in vivo process 
of PDAC progression.
To further strengthen our finding of endothelial ablation in 
PDAC in vivo, we sought to demonstrate the presence of blood 
vessels occupied by tumor cells in a genetically engineered mouse 
model (GEMM) of PDAC, in which many aspects of human tumor 
biology and progression are captured (22). In this GEMM, tumor 
cells were genetically tagged with a yellow fluorescent protein, and 
PDAC tumor tissue sections were immunohistochemically stained 
for endomucin and collagen IV to highlight the endothelium and 
their basement membrane protein. Similar to the ectopic model, 
tumor cells in the GEMM were also found at the luminal side of 
blood vessels (Fig. 2C). Together, our findings in both in vivo tumor 
mouse models and our 3D biomimetic model suggest that PDAC 
invades blood vessels, gains access to the luminal space of the blood 
vessels, and ultimately ablates the endothelium to form tumor 
cell–lined luminal structures, a process that may contribute to the 
hypovascularity observed in larger PDAC tumor masses.
Endothelial ablation in PDAC is mediated through 
a transforming growth factor– receptor signaling pathway
We next sought to identify which signaling pathways were involved 
in endothelial ablation. The transforming growth factor– (TGF­) 
signaling pathway has been implicated in tumor progression in 
many different types of tumors, including PDAC (23). We therefore 
asked whether the TGF­ receptor signaling pathway was involved 
in endothelial ablation in PDAC. Using our 3D organotypic model, 
we allowed pancreatic cancer cells from the pancreatic cancer duct 
to invade the engineered blood vessel. Once the pancreatic cancer 
cells reached the blood vessels, we initiated treatment with SB431542 
at 5 M for a duration of 7 days. We observed that inhibition of 
TGF­ receptor signaling significantly reduced the ablation of 
endothelial cells by pancreatic cancer cells in our biomimetic blood 
vessel (Fig. 3A, i and ii, and fig. S8, A and B). Quantification of the 
endothelial cell vessel area that was ablated by PDAC cells further 
confirmed our observation (Fig. 3A). Western blot of phosphorylated 
Smad2 confirmed the effect of SB431542 inhibition on TGF­ 
receptor signaling in both endothelial cells and PD7591 (Fig. 3A).
We further investigated whether inhibition of TGF­ receptor 
signaling also led to reduced endothelial ablation in vivo by subcu­
taneously injecting the same pancreatic cancer cell line PD7591 into 
mice. By day 9, when the tumor reached 100 mm3, we administered 
SB431542 versus control vehicle into two groups of mice through 
daily peritoneal injections for 1 and 2 weeks. In tumors harvested 
from SB431542­treated mice, we measured a higher density of 
vessels by quantifying the CD31 signal intensity within the tumor 
microenvironment (Fig. 3B and fig. S5B). We also noticed a minimal 
proliferation of endothelial cells in both control and SB431542­treated 
tumors (fig. S5C), indirectly suggesting that the increase in CD31 
signal intensity in SB431542­treated tumors was likely due to less 
endothelial cell ablation. Similarly, quantification of cleaved caspase­3 
signal intensity showed a less apoptotic signal in endothelial cells in 
SB431542­treated mice at 1 and 2 weeks versus control mice. However, 
endothelial cell ablation and apoptosis were not fully inhibited, as 
the apoptotic caspase signal was still higher at 2 weeks versus 1 week. 
Of note, the tumor growth rate was not affected by administration 
of SB431542 in vivo (fig. S5D). Together, our in vitro and in vivo 
data suggested that inhibiting TGF­ receptor signaling reduces 
endothelial ablation in PDAC.
Endothelial ablation of PDAC is mediated through 
an activin-ALK7 pathway
Because SB431542 has previously been reported as a broad inhibitor 
for the TGF­ superfamily receptors ALK4, ALK5, and ALK7 (24), 
we sought to determine which of these receptors in each of the cell 
types might contribute to endothelial ablation. To address this 
question, we designed a simple 2D patterned coculture invasion 
assay to quickly enable us to identify the molecular mechanism of 
endothelial cell ablation. Briefly, PDAC cells were plated inside a 
silicone annulus, while endothelial cells were plated outside the 
annulus. Peeling the annulus off the substrate left a circular popula­
tion of PDAC cells surrounded by a monolayer of endothelial cells 
(Fig. 4A). As time progressed, the PDAC cells invaded into the 
endothelial cell area and ablated the endothelial cells (movie S3), 
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resulting in an increase in the area of PDAC cells (Fig. 4B and 
fig. S9A). When SB431542 was added into the coculture of PD7591 
and endothelial cells, the PDAC invasion area was significantly 
decreased (Fig. 4B, fig. S9B, and movie S4), resembling the effects of 
blocking the TGF­ receptor signaling pathway to prevent endothelial 
ablation in our 3D organotypic model. We further showed the 
effects of inhibiting the TGF­ receptor signaling pathway to reduce 
endothelial ablation in two other human pancreatic cancer cell lines 
(Panc­1 and BxPC­3; fig. S6, A and B).
Using this 2D patterned coculture invasion assay, we first stained for 
cleaved caspase­3 activity to examine whether apoptosis coincided 
with PDAC invasion of the endothelial cell area. In agreement with 
our findings in the 3D organotypic model, the cleaved caspase­3 
signal was only detected in endothelial cells, and the cleaved caspase­3 
signal intensity in endothelial cells was the highest at the interface 
between endothelial and tumor cells and dropped as the endothelial 
cells were further away from the interface (fig. S6C). Administration of 
SB431542 significantly reduced the number of apoptotic endothelial 
cells, particularly at the interface between endothelial and cancer 
cells (fig. S6C), suggesting that direct contact between endothelial 
and PDAC cells may be required for endothelial ablation. To test 
this hypothesis, we monitored the endothelial­PDAC interface 
using time­lapse microscopy and found that endothelial cells begin 
to round up and detach from the substrate, two characteristics that 
are reminiscent of apoptosis, 8 hours after contact with the invading 
tumor cells (fig. S6D). Treatment of an endothelial monolayer with 
tumor­conditioned medium did not increase apoptosis, suggesting 
that the apoptotic signal is not soluble (fig. S7A). In contrast, endo­
thelial cell ablation was reduced when proliferation of tumor cells was 
inhibited with aphidicolin (fig. S7B). Together, these data suggest that 
proliferation of the tumor cells and direct contact between endothe­
lial and tumor cells are required for endothelial cell ablation to occur.
Fig. 2. Endothelial ablation is observed in in vivo mouse tumor models (subcutaneous tumor implantation model and genetically engineered mouse model). 
(A) Examination of endothelial cells in the ectopic mouse tumors in vivo. YFP PD7591 (in green) was subcutaneously injected into mice for 14 days. Apoptotic endothelial 
cells were also observed in the in vivo tumor microenvironment, similarly to the observation in the 3D organotypic model. Apoptotic endothelial cells (in red) were 
marked by cleaved caspase-3 signal (in white). (B) Endothelial ablation in subcutaneous tumor implantation model. Resected tumors at day 14 exhibited partial ablation 
of endothelial cells by pancreatic cancer cells (red arrows) in hybrid blood vessels. Some small vessels, decorated with collagen IV (in white), a basement membrane 
protein, demonstrated complete endothelial ablation by YFP PD7591 in the luminal side of the vessels (yellow arrows). Blood vessels were stained with anti-mouse 
endomucin antibody (in red). (C) Endothelial ablation was observed in GEMM of PDAC. Partial ablation of endothelium in the blood vessel was indicated by red arrows, 
where the blood vessel displayed the occupation of yellow fluorescent protein (YFP) tumor cells in place of the endothelium. Endothelial cells in all images were stained with 
either anti-mouse CD31 antibody or anti-mouse endomucin. YFP PD7591 was restained with FITC-conjugated anti-GFP antibody. Cell nuclei were stained with DAPI (in blue).
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Because SB431542 exerted its effects in both endothelial and 
PDAC cells, we first used this system to investigate whether ALK4, 
ALK5, or ALK7 in endothelial cells played a role in endothelial 
ablation. We genetically deleted receptors ALK4, ALK5, and ALK7 in 
the endothelial cells using CRISPR­Cas9 technology and plated 
wild­type PD7591 and ALK4, ALK5, or ALK7 knockout human 
umbilical vein endothelial cells (HUVECs) in the 2D patterned 
coculture invasion assay. Unexpectedly, the quantified invasion 
area of PD7591 showed no significant difference between ALK4, 
ALK5, or ALK7 knockout and scramble HUVEC conditions (fig. 
S7, C to E). Knockout of ALK4, ALK5, and ALK7 also did not affect 
the population doubling time of endothelial cells (fig. S7F). These 
Fig. 3. Inhibition of the TGF- receptor signaling pathway significantly reduced endothelial ablation. (A) Inhibition of TGF- receptor signaling pathway with 
SB431542 in 3D organotypic model. PDAC tumor cells from the pancreatic cancer duct were allowed to invade into the biomimetic vessels. Once the PDAC tumor cells 
reached the blood vessels, 5 M SB431542 or dimethyl sulfoxide (DMSO) was administered for 7 days. Representative confocal images of vessels treated with SB431542 
(i) and DMSO (ii) in 3D organotypic model. The percentage of endothelium-ablated area showed that SB431542 significantly reduced the endothelial ablation in 3D 
organotypic model (n = 4 individual experiments). Western blot for phosphorylated Smad2 in endothelial cells and PD7591 in 2D monoculture confirmed the effectiveness 
of SB431542 to inhibit the TGF- signaling pathway in endothelial cells and in pancreatic cancer cells PD7591. (B) Inhibition of TGF- receptor signaling pathway with 
SB431542 in a mouse tumor model for either 1 or 2 weeks. SB431542 was peritoneally administered into the mice daily for 1 and 2 weeks. Mice were sacrificed at days 16 
and 23. Quantification of endothelial cell density revealed a significantly higher endothelial cell density within the tumors treated with SB431542 as compared to vehicle 
control (n = 5 mice per experimental group) for both 1 and 2 weeks. Cleaved caspase-3 activity in endothelial cells was also less in SB431542-treated tumors versus control 
tumors in both 1 and 2 weeks. Cleaved caspase-3 activity was significantly increased in tumors treated with SB431542 for 2 weeks versus 1 week. Right: Representative 
images of tumor samples in vehicle control DMSO and SB431542 conditions for 1-week condition. Endothelial cells were stained with anti-mouse CD31 antibody. YFP 
PD7591 was restained with FITC-conjugated anti-GFP antibody. Cell nuclei were stained with DAPI (in blue). *P < 0.05, **P < 0.01, and ***P < 0.001 indicate statistical 
significance. NS, not significant. Two-tailed Student’s t test. Error bars are SEM.
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Fig. 4. Endothelial ablation required activin-ALK7 signaling in the invasive PDAC. (A) A schematic demonstrates a setup for 2D patterned coculture of PDAC and 
endothelial cells. Tumor cells were plated inside an annulus, and endothelial cells were plated outside the annulus. Once the annulus was removed, tumor invaded into 
the endothelial cells, resulting in an expansion of the tumor area. (B) SB431542 reduced endothelial ablation in 2D patterned coculture (n = 3 individual experiments). 
(C) ALK7 was knocked out in YFP PD7591 by CRISPR-Cas9 and plated in 2D patterned cocultures with wild-type (WT) HUVECs. Invasion area of ALK7 knockout (KO) YFP 
PD7591 was significantly less than scramble PD7591, suggesting the role of ALK7 in PD7591 to mediate endothelial ablation (n = 3 individual experiments). (D) Inhibin A 
and inhibin B, major subunits of activins, were up-regulated in pancreatic cancer cells as compared to normal mouse pancreatic ductal epithelial cells (mPDE) (n = 3 
individual experiments). (E) Inhibition of activin with the endogenous inhibitor follistatin significantly diminished endothelial ablation of PDAC in 2D patterned cocultures 
(n = 3 individual experiments). (F) Inhibition of activin by follistatin (200 ng/ml) in 3D organotypic model revealed a significant reduction in tumor replaced blood vessel 
(n = 3 individual experiments). (G) In vivo mouse tumor model to confirm the role of ALK7 in endothelial ablation. ALK7 knockout PD7591 versus scramble cells were 
subcutaneously implanted into mice for 2 weeks. Cleaved caspase-3 signal indicated a substantial reduction in apoptotic endothelial cells in ALK7 knockout condition 
versus scrambled PD7591 condition (n = 5 mice per experimental group). A significant increase in endothelial cell density was also observed with ALK7 knockout PD7591 
tumors versus scramble PD7591 tumors (n = 5 mice per experimental group). (i) Representative images of tumors implanted with scramble PD7591 depicted less endothelial 
cell density and high apoptotic signal. (ii) Representative images of tumor implanted with ALK7 knockout PD7591 depicted high endothelial cell density and less apoptotic 
signal. *P < 0.05, **P < 0.01, and ***P < 0.001 indicate statistical significance. Two-tailed Student’s t test. Error bars are SEM.
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data strongly suggested the involvement of the TGF­ superfamily 
receptors in pancreatic cancer cells rather than in endothelial cells.
When ALK7 was knocked out in PD7591 cells, cellular invasion 
and endothelial ablation of PD7591 in 2D patterned cocultures 
(Fig. 4C and fig. S7H) were significantly reduced, while CRISPR­ 
mediated knockout of ALK5 in PD7591 cells did not reduce 
endothelial ablation (fig. S7I). Knockout of ALK4 was not possible 
in these cancer cells despite multiple attempts with different guide 
RNA sequences, suggesting a requirement for ALK4 in these 
cells. Knockout of ALK7, but not ALK5, significantly prolonged 
the doubling time of PD7591 (fig. S7G), further supporting the no­
tion that proliferation of tumor cells is likely involved in endo­
thelial cell ablation.
Next, we sought to identify the ligand for the ALK7 signaling, as 
ALK7 can be activated via different ligands, such as nodal and 
activin. The major subunits of activin (inhibin A and B), in 
particular, were found to be highly up­regulated in the PDAC cells 
as compared to the normal mouse pancreatic ductal epithelial cells 
(Fig. 4D). We then exposed PDAC cells to follistatin, a naturally 
occurring activin inhibitor (25), in our 2D patterned coculture and 
in our 3D organotypic model. Inhibition of activin resulted in a 
significant reduction in endothelial ablation in 2D (Fig. 4E) and in 
a reduction of vessel replaced area in the 3D organotypic model 
(Fig. 4F and fig. S8, C and D), suggesting the involvement of activin 
in ALK7 activation during the process of endothelial ablation.
To further confirm the role of ALK7 in endothelial ablation, we 
knocked out ALK7 expression in PD7591 and subcutaneously 
implanted these tumor cells into mice. Tumors were allowed to 
grow for 2 weeks before they were resected. These tumors exhibited 
slower growth compared to control tumors (fig. S5E). Two weeks 
after tumor implantation, the tumors were resected and examined 
for vessel density and apoptotic endothelial cells. The ALK7­deficient 
tumors displayed a significantly higher vessel density and less apoptotic 
endothelial cells within the tumor mass as compared to scramble­treated 
control mice (Fig. 4G). Together, our in vitro and in vivo findings 
affirmed a role for ALK7 in mediating endothelial ablation during 
tumor invasion in PDAC.
DISCUSSION
In contrast to many tumors that are highly angiogenic, PDAC is 
poorly vascularized (7, 26), a paradoxical finding in light of the fact 
that pancreatic cancer cells are also known to express and secrete a 
plethora of proangiogenic factors (27). Using our 3D organotypic 
model to recapitulate invasion of PDAC tumor cells to blood 
vessels, we observed that PDAC tumor cells rapidly penetrated the 
lumen of blood vessels and ablated the endothelial cells, ultimately 
leaving lumens lined by tumor cells. We refer to this process as 
endothelial ablation. Furthermore, through histologic costaining of 
vascular basement membranes, endothelial cells, and PDAC cells 
within mouse tumor models, we observed that endothelial ablation 
by PDAC tumors occurs in the in vivo setting. Our study is consis­
tent with histologic studies of PDAC patient tumors, which have 
reported luminal walls of arteriolar vessels that were lined by cuboidal 
epithelial cells in place of normal endothelium (8–10). Our study 
suggests that one factor contributing to the apparent microvascular 
hypovascularity of PDAC is not a result of reduced angiogenesis per se, 
but instead a result of endothelial ablation triggered by the invading 
tumor cells. These invading tumor cells exhibited a faster growth 
rate than the endothelial cells and eventually led to apoptosis in 
tumor endothelial cells and subsequently diminished the number of 
functional blood vessels in the PDAC tumor microenvironment. 
Perhaps, our observation of tumor endothelial cell ablation in PDAC 
fits a classical concept of cell­cell competition, which describes 
clearance of “loser cells” by “winner cells” based on their fitness 
differences within the local environment such as their cellular divi­
sion potential (28).
The ability of PDAC tumors to rapidly invade into the vessel, 
ablate the endothelium, and occupy the vessel lumen could explain the 
high rate of circulating tumor cells and metastatic load of PDAC. A 
similar mechanism, where tumor cells ablate the stromal cells, has 
been reported in a study of ovarian cancer (29). In that study, after 
ovarian cancer spheroids were plated on a monolayer of endometrial 
cells, the ovarian cancer cells began to spread over the endometrial 
monolayer and displaced the endometrial cells. A histologic study 
of ovarian cancer in human patients also reported the absence of the 
endometrium due to the penetration of ovarian cancer cells into the 
endometrium (30). In the context of these studies, our work suggests 
that carcinoma cells have the capacity to clear and ablate luminal 
compartments within the tumor microenvironment. It would be 
interesting to examine this phenomenon of endothelial ablation or 
stromal ablation in other types of cancer.
Apart from proposing a possible mechanism for the apparent 
hypovascularity in PDAC, our study unveils a crucial role for activin­ 
ALK7 signaling to contribute to endothelial ablation. Although the 
functional roles of TGF­ and TGF­ receptor signaling have been 
investigated in cancer progression, little is known about the contri­
bution of activin and ALK7 to pancreatic cancer. In ovarian cancer, 
hepatoma, and breast cancer, ALK7 serves as a tumor­suppressive 
receptor to induce apoptosis in cancer cells or prevent cancer 
progression (31–33). In contrast, overexpression of ALK7 has been 
reported to be a marker for poor prognosis in gallbladder cancer 
(34). ALK7 is a receptor for both nodal and activin (35). Nodal has 
been reported to mediate vascular mimicry in melanomas, wherein 
cancer cells formed perfused tubular structures and coexpressed 
endothelial cell markers (36). Additionally, nodal has also been 
found to initiate cancer stem cells in pancreatic cancer (37). In 
contrast, the role of activin in tumor progression has remained 
largely unappreciated, although activin levels in plasma have been 
associated with poor prognosis (38) and are overexpressed in multiple 
human pancreatic cancer cells (39). These reports and our findings 
together suggest that further investigations into the role of the 
activin­ALK7 axis in PDAC progression are warranted.
In this study, we use a 3D organotypic model to demonstrate 
that tumor–endothelial cell interactions not only are restricted to 
intravasation, extravasation, and vascular mimicry (36, 40) but also 
include the process of endothelial ablation within the blood vessels, 
a process that requires further study. Our simple model of PDAC 
and blood vessels provided sufficient complexity to reveal this 
process, yet allowed us to introduce genetic and spatiotemporal 
control to isolate signaling pathways involved for each cell type. 
Going forward, inclusion of vascular mural cells, and immune cells, 
or varying the composition of extracellular matrices could be intro­
duced in this engineered 3D organotypic model to more faithfully 
study the roles of the tumor microenvironments during tumor 
progression in vitro. Although existing in vivo mouse models 
provide great opportunities to capture the progression of cancer, 
dissecting the molecular mechanisms and cell­cell interactions is 
Nguyen et al., Sci. Adv. 2019; 5 : eaav6789     28 August 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
8 of 9
often difficult because of the complexity of in vivo models. Thus, 
as demonstrated here, 3D organotypic models provide an important 
complement to understand these complex cellular interactions with 
more mechanistic insight.
MATERIALS AND METHODS
Our device was microfabricated as previously described (18). Briefly, 
the polydimethylsiloxane (PDMS) device was assembled by bonding 
a bilayer PDMS gasket on top of a glass coverslip. Rat tail collagen 1 
(Corning) was prepared at 2.5 mg/ml following the manufacturer’s 
instructions and was injected into the PDMS device to surround two 
300­m acupuncture needles (Hwato). After collagen polymerizes, 
acupuncture needles were withdrawn. HUVECs (Lonza) were seeded 
into one of the channels, while pancreatic cancer cells were seeded 
into the other channel. FBS (Atlanta Biologicals) was added at 10% 
(v/v) concentration into the HUVEC channel to generate a gradient 
of chemoattractants to trigger migration of pancreatic cancer.
KrasLSL­G12D; p53L/+; Pdx1­cre; Rosa26YFP/YFP (KPCY) tissues 
were a gift from B.Z.S.’s laboratory (University of Pennsylvania). 
The model has been described previously (5). Briefly, mice were 
palpated and examined for evidence of morbidity twice per week. 
Tumor­bearing animals were sacrificed when morbid, and primary 
pancreatic tumors were collected from mice aged 14 to 30 weeks. 
Tissues were flash­frozen in OCT (optimal cutting temperature) 
and subsequently processed for immunofluorescent staining.
Detailed explanations of the materials and methods used in this 
study can be found in the Supplementary Materials.
SUPPLEMENTARY MATERIALS
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Fig. S1. Screening for chemoattractants for pancreatic cancer cell invasions and 
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Fig. S3. Vascular invasion and endothelial ablation were observed in multiple primary murine 
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Fig. S6. Inhibition of the TGF- receptor signaling pathway reduced the endothelial ablation in 
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Movie S2. YFP PD7591 (in green) invaded toward the biomimetic blood vessel (stained with CD31 in red).
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invasion assay in the presence of vehicle control (dimethyl sulfoxide).
Movie S4. YFP PD7591 (in green) and HUVECs (in phase) were plated in 2D patterned coculture 
invasion assay in the presence of 5 M SB431542.
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